380 related articles for article (PubMed ID: 29765840)
1. Synaptic Failure: Focus in an Integrative View of ALS.
Casas C; Manzano R; Vaz R; Osta R; Brites D
Brain Plast; 2016 Jun; 1(2):159-175. PubMed ID: 29765840
[TBL] [Abstract][Full Text] [Related]
2. Opposite Synaptic Alterations at the Neuromuscular Junction in an ALS Mouse Model: When Motor Units Matter.
Tremblay E; Martineau É; Robitaille R
J Neurosci; 2017 Sep; 37(37):8901-8918. PubMed ID: 28821658
[TBL] [Abstract][Full Text] [Related]
3. Microglia centered pathogenesis in ALS: insights in cell interconnectivity.
Brites D; Vaz AR
Front Cell Neurosci; 2014; 8():117. PubMed ID: 24904276
[TBL] [Abstract][Full Text] [Related]
4. Axonal degeneration, distal collateral branching and neuromuscular junction architecture alterations occur prior to symptom onset in the SOD1(G93A) mouse model of amyotrophic lateral sclerosis.
Clark JA; Southam KA; Blizzard CA; King AE; Dickson TC
J Chem Neuroanat; 2016 Oct; 76(Pt A):35-47. PubMed ID: 27038603
[TBL] [Abstract][Full Text] [Related]
5. Motor neuron vulnerability and resistance in amyotrophic lateral sclerosis.
Nijssen J; Comley LH; Hedlund E
Acta Neuropathol; 2017 Jun; 133(6):863-885. PubMed ID: 28409282
[TBL] [Abstract][Full Text] [Related]
6. The expression of the chemorepellent Semaphorin 3A is selectively induced in terminal Schwann cells of a subset of neuromuscular synapses that display limited anatomical plasticity and enhanced vulnerability in motor neuron disease.
De Winter F; Vo T; Stam FJ; Wisman LA; Bär PR; Niclou SP; van Muiswinkel FL; Verhaagen J
Mol Cell Neurosci; 2006; 32(1-2):102-17. PubMed ID: 16677822
[TBL] [Abstract][Full Text] [Related]
7. Expression of a Mutant SEMA3A Protein with Diminished Signalling Capacity Does Not Alter ALS-Related Motor Decline, or Confer Changes in NMJ Plasticity after BotoxA-Induced Paralysis of Male Gastrocnemic Muscle.
Moloney EB; Hobo B; De Winter F; Verhaagen J
PLoS One; 2017; 12(1):e0170314. PubMed ID: 28103314
[TBL] [Abstract][Full Text] [Related]
8. New perspectives on amyotrophic lateral sclerosis: the role of glial cells at the neuromuscular junction.
Arbour D; Vande Velde C; Robitaille R
J Physiol; 2017 Feb; 595(3):647-661. PubMed ID: 27633977
[TBL] [Abstract][Full Text] [Related]
9. Early and persistent abnormal decoding by glial cells at the neuromuscular junction in an ALS model.
Arbour D; Tremblay E; Martineau É; Julien JP; Robitaille R
J Neurosci; 2015 Jan; 35(2):688-706. PubMed ID: 25589763
[TBL] [Abstract][Full Text] [Related]
10. Dynamic changes of CX3CL1/CX3CR1 axis during microglial activation and motor neuron loss in the spinal cord of ALS mouse model.
Zhang J; Liu Y; Liu X; Li S; Cheng C; Chen S; Le W
Transl Neurodegener; 2018; 7():35. PubMed ID: 30607245
[TBL] [Abstract][Full Text] [Related]
11. The Cell Autonomous and Non-Cell Autonomous Aspects of Neuronal Vulnerability and Resilience in Amyotrophic Lateral Sclerosis.
Schweingruber C; Hedlund E
Biology (Basel); 2022 Aug; 11(8):. PubMed ID: 36009818
[TBL] [Abstract][Full Text] [Related]
12. Skeletal muscle-restricted expression of human SOD1 causes motor neuron degeneration in transgenic mice.
Wong M; Martin LJ
Hum Mol Genet; 2010 Jun; 19(11):2284-302. PubMed ID: 20223753
[TBL] [Abstract][Full Text] [Related]
13. Gamma motor neurons survive and exacerbate alpha motor neuron degeneration in ALS.
Lalancette-Hebert M; Sharma A; Lyashchenko AK; Shneider NA
Proc Natl Acad Sci U S A; 2016 Dec; 113(51):E8316-E8325. PubMed ID: 27930290
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA Profiling Reveals Marker of Motor Neuron Disease in ALS Models.
Hoye ML; Koval ED; Wegener AJ; Hyman TS; Yang C; O'Brien DR; Miller RL; Cole T; Schoch KM; Shen T; Kunikata T; Richard JP; Gutmann DH; Maragakis NJ; Kordasiewicz HB; Dougherty JD; Miller TM
J Neurosci; 2017 May; 37(22):5574-5586. PubMed ID: 28416596
[TBL] [Abstract][Full Text] [Related]
15. Driven to decay: Excitability and synaptic abnormalities in amyotrophic lateral sclerosis.
Fogarty MJ
Brain Res Bull; 2018 Jun; 140():318-333. PubMed ID: 29870780
[TBL] [Abstract][Full Text] [Related]
16. Cross-disease comparison of amyotrophic lateral sclerosis and spinal muscular atrophy reveals conservation of selective vulnerability but differential neuromuscular junction pathology.
Comley LH; Nijssen J; Frost-Nylen J; Hedlund E
J Comp Neurol; 2016 May; 524(7):1424-42. PubMed ID: 26502195
[TBL] [Abstract][Full Text] [Related]
17. Neuromuscular Junction Dismantling in Amyotrophic Lateral Sclerosis.
Cappello V; Francolini M
Int J Mol Sci; 2017 Oct; 18(10):. PubMed ID: 28972545
[TBL] [Abstract][Full Text] [Related]
18. An
Altman T; Geller D; Kleeblatt E; Gradus-Perry T; Perlson E
J Cell Sci; 2019 Dec; 132(23):. PubMed ID: 31722980
[TBL] [Abstract][Full Text] [Related]
19. ALS as a distal axonopathy: molecular mechanisms affecting neuromuscular junction stability in the presymptomatic stages of the disease.
Moloney EB; de Winter F; Verhaagen J
Front Neurosci; 2014; 8():252. PubMed ID: 25177267
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
